Lawrence Blatt - Feb 4, 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Executive Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt
Stock symbol
ALGS
Transactions as of
Feb 4, 2022
Transactions value $
$0
Form type
4
Date filed
2/8/2022, 03:09 PM
Next filing
Jul 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +323K $0.00 323K Feb 4, 2022 Common Stock 323K $3.06 Direct F1
transaction ALGS Stock Option (Right to Buy) Award $0 +80.9K $0.00 80.9K Feb 4, 2022 Common Stock 80.9K $3.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F2 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date.